Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics, Inc. (Nasdaq: AGRX) is a forward-thinking company specializing in women's healthcare. Their mission is to address the unmet health needs of today’s women by providing innovative contraceptive options. The company’s leading product, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), is a once-weekly prescription contraceptive patch that offers an alternative to daily pills or longer-acting methods. Twirla employs Agile's proprietary Skinfusion® technology designed to improve patch adhesion and patient comfort.
Recently, Agile Therapeutics has reported significant financial and operational accomplishments. In the third quarter of 2023, Twirla achieved net revenue of $6.7 million, reflecting a 21% increase from the second quarter and a 122% increase year-over-year. The company projects positive cash flow from operations by the first quarter of 2024, backed by a strong gross margin that grew to 63% in the third quarter of 2023.
The company’s strategic focus includes expanding their market presence through partnerships and promotional efforts, notably targeting five key states with high reimbursement potential. Agile is also enhancing Twirla's availability through telemedicine platforms like Nurx, TwentyEight Health, and Pandia, aiming to broaden its reach further.
Operational expenses have been managed effectively, with a reported decrease in GAAP operating expenses to $8.2 million in the third quarter of 2023. This financial discipline, alongside the anticipated revenue, positions Agile Therapeutics favorably for sustainable growth.
Additionally, Agile Therapeutics has successfully completed the pay-off of their debt facility with Perceptive Advisors, leaving their balance sheet debt-free. Despite a delisting notice from Nasdaq, the company’s shares continue to trade on the OTC Market, maintaining its focus on executing its business plan and exploring strategic opportunities to maximize Twirla’s growth and shareholder value.
For more detailed updates, latest news, and information, you can visit their website at www.agiletherapeutics.com or follow them on Twitter @agilether.
Agile Therapeutics (Nasdaq: AGRX) has launched Twirla, the first and only once-weekly contraceptive patch in the U.S. It delivers a low-dose combination of levonorgestrel and ethinyl estradiol, targeting women with a BMI less than 30 kg/m². Twirla is designed for convenience and less frequent administration compared to daily pills, with a commitment to accessibility and affordability for users. Safety warnings include reduced effectiveness in women with higher BMI, cardiovascular risks for smokers, and other contraindications. The patch is supported by resources like "The Loop" for user education.
Agile Therapeutics (Nasdaq: AGRX) announced the publication of primary results from the Phase 3 SECURE study of Twirla®, a transdermal contraceptive system, in the journal Contraception. The study, which included 2,032 women, evaluated Twirla's efficacy, safety, and tolerability. It was approved by the FDA on February 14, 2020, for women with a BMI < 30 kg/m². The publication is expected to provide healthcare providers with vital information to enhance shared decision-making regarding contraceptive options.
Agile Therapeutics (Nasdaq: AGRX) announced that CEO Al Altomari will participate in a virtual fireside chat at the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The pre-recorded chat is available on the company's website from 10:00am ET on November 23 through December 3. Agile is a women's healthcare company focusing on fulfilling unmet health needs, particularly in contraceptive options, with its product Twirla®, a non-daily prescription contraceptive.
Agile Therapeutics (AGRX) announced its financial results for Q3 2020, reporting $71.9 million in cash and equivalents as of September 30. The company is on track for the commercial launch of Twirla, expected by year-end 2020, with all three validation batches ready for release. The net loss for the quarter increased to $15.5 million, or $0.18 per share, compared to $4.4 million the previous year. Operating expenses narrowed to $52-$54 million for 2020, with significant investments in sales and marketing.
Agile Therapeutics (Nasdaq: AGRX) announces it will release its third quarter 2020 financial results on November 12, 2020, after market close. A live conference call and webcast will follow at 4:30 p.m. ET for discussing the results and providing a business update. Investors can join the conference call by calling (877) 407-2991 for U.S. callers or (201) 389-0925 internationally. The company focuses on women's healthcare, particularly offering contraceptive options through its product Twirla®, utilizing its Skinfusion® transdermal technology.
Agile Therapeutics, a women's healthcare company traded under the symbol AGRX, will have Chairman and CEO Al Altomari present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020, at 3:20 PM EDT. The presentation will be available via a live webcast, and an archived version will be accessible on the company’s website for 30 days.
Agile focuses on developing contraceptive options, including its product Twirla®, a non-daily prescription contraceptive using proprietary Skinfusion® technology.
Agile Therapeutics, a women’s healthcare firm, announced that CEO Al Altomari will engage in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference. This event is scheduled for September 16, 2020, at 11:30 a.m. EDT. A live webcast will be accessible on the company’s Investor Relations page, with an archived version available for 30 days post-event. Agile is dedicated to addressing women’s healthcare needs and offers innovative contraceptive solutions via its product, Twirla®, a transdermal contraceptive system.
Agile Therapeutics (Nasdaq: AGRX) announced a virtual Investor/Analyst Day on September 21, 2020, from 11:00 AM to 1:00 PM EDT. Key executives will discuss the Twirla commercial program, including launch activities and marketing strategies. Presenters include CEO Al Altomari, CFO Dennis Reilly, and notable speakers from the OB/GYN field. A live audio webcast will be available, and an archived version can be accessed for 30 days post-event. Twirla is a non-daily contraceptive patch designed to meet women's health needs.
Agile Therapeutics (Nasdaq: AGRX) has launched the I'm So Done campaign, aimed at empowering women to actively participate in their contraceptive choices. This initiative focuses on educating women about different birth control options and encourages dialogue with healthcare providers. The campaign emphasizes the importance of informed decision-making in contraceptive care. According to the Guttmacher Institute, women seeking two children will use contraception for about three decades, highlighting the need for diverse choices throughout their lives.
Agile Therapeutics, a women's healthcare company, announced that its CEO, Al Altomari, will participate in a panel at Maxim Group’s M-Vest Virtual Conference on August 13, 2020, at 10:00 a.m. Eastern Time. This event will be moderated by Jason McCarthy, a biotechnology analyst at Maxim Group. Agile Therapeutics focuses on providing innovative contraceptive options, including its non-daily prescription system, Twirla. For registration details, visit here.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
What is Agile Therapeutics' primary product?
How well did Agile Therapeutics perform financially in the third quarter of 2023?
What is Skinfusion® technology?
What are the company's future financial projections?
How is the company expanding its market presence?
What are the current trading circumstances of Agile Therapeutics' shares?
How did Agile Therapeutics manage their operational expenses?
What strategic initiatives is Agile Therapeutics currently pursuing?
What impact does the Biden-Harris Administration's new guidance have on Twirla?
Where can more information about Agile Therapeutics be found?
